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The median survival of patients with newly diag-nosed glioblastoma treated according to the Stupp treatment protocol is 14.6 months.25 This approach 
has been supported by the results of a large Phase III trial, 
thus becoming the standard of therapy in newly diagnosed 
glioblastoma,24 despite a long-standing practice of thera-
py with a number of chemotherapeutic agents and with 
evidence of efficacy suggested only by meta-analysis.12 
However, glioblastoma invariably recurs, most frequent-
ly in the proximity of the original tumor site, and more 
rarely at a distance or as a multifocal or diffuse tumor.5 
After recurrence, median survival time does not exceed 
9–10 months, even in the setting of Phase II trials with 
novel agents such as bevacizumab.8,17
Locoregional chemotherapy has been assessed with 
the use of carmustine wafers (Gliadel, manufactured by 
Eisai) positioned by the neurosurgeon in the surgical cav-
ity. After evidence of increased survival after recurrence 
following repeat surgery and carmustine wafers, as com-
pared with repeat surgery alone,4 a trial was performed in 
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Object. Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation 
therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant 
radiochemotherapy with temozolomide. A combination of carmustine wafers with the Stupp treatment regimen has 
only been investigated in retrospective studies.
Methods. In a single-institution prospective study, the authors assessed 12-month progression-free survival 
(PFS), toxicity, and overall survival in patients with glioblastoma treated with surgery, carmustine wafers, radiother-
apy, and 6-month metronomic temozolomide chemotherapy. Thirty-five patients with de novo glioblastoma, between 
the ages of 18 and 70 years, and with Karnofsky Performance Scale scores of at least 70, were included in the study. 
Patients were followed monthly and assessed using MRI every 2 months.
Results. After a median follow-up of 15 months, the median time to tumor progression was 12.5 months and 
median survival was 17.8 months. Due to toxicity (mostly hematological), 7 patients had to prematurely stop te-
mozolomide treatment. Twenty-two patients developed Grade 3 CD4+ lymphocytopenia. Three patients developed 
oral-esophageal candidiasis, 2 developed pneumonia, and 1 developed a dorsolumbar zoster. Early intracranial hy-
pertension was observed in 1 patient, and 1 was treated empirically for suspected brain abscess. One patient died of 
Legionella pneumonia soon after repeat surgery.
Conclusions. Overall, this treatment schedule produced promising results in terms of PFS without a marked 
increase in toxicities as compared with the Stupp regimen. However, the gain in median survival using this schedule 
was less clear. Only prospective comparative trials will determine whether these preliminary results will translate into 
a long-term survival advantage with an acceptable toxicity profile.
(http://thejns.org/doi/abs/10.3171/2012.12.JNS111893)
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Abbreviations used in this paper: CTCAE = Common Terminol-
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= polymerase chain reaction; PFS = progression-free survival; RPA 
= recursive partitioning analysis.
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2003.30 The results of this trial suggested some survival 
advantage of using carmustine wafers combined with ra-
diotherapy in newly diagnosed glioblastoma, but without 
the addition of temozolomide.30
To increase antitumoral activity in the treatment pro-
tocols, several studies have addressed the feasibility of 
combining carmustine wafers with the Stupp treatment 
protocol, with results showing a variable profile of tol-
erability and toxicity and possibly interesting effects on 
PFS and median survival time.3,11,14,17,18,21 Multimodal ap-
proaches are increasingly being advocated in the treat-
ment of aggressive tumors, including glioblastoma. The 
reasons for this advocacy include the presence within the 
tumor of heterogeneous genetic abnormalities27 as well as 
the inability of the presently adopted treatment schedules 
to effectively prolong PFS and overall survival in a clini-
cally meaningful way.
In the present study we investigated the tolerability 
and possible efficacy of local carmustine wafers in com-
bination with radiotherapy and prolonged metronomic 
temozolomide chemotherapy in patients with newly di-
agnosed glioblastoma who had undergone resection. The 
rationale for choosing a metronomic schedule of temo-
zolomide is a possible effect on MGMT activity even in 
patients with a nonmethylated MGMT promoter,27,28 as 
well as a possible antiangiogenic effect in the context of 
minimal residual disease after surgery.10 Moreover, be-
ginning chemotherapy 2 weeks after surgery may result 
in increased killing of residual tumor cells before the be-
ginning of radiation therapy, adding systemic chemother-
apy to the effects of carmustine released locally by surgi-
cally placed implants. We report the preliminary data of 
a prospective single-institution Phase II study involving 
carmustine wafers at surgery combined with radiation 
therapy and protracted metronomic temozolomide in pa-
tients with newly diagnosed glioblastoma.
Methods
Study Population
The study protocol was approved by the Ethical 
Committee of Fondazione IRCCS Istituto Neurologico C. 
Besta. The design of the study was a 2-phase investiga-
tion according to the recommendations of Simon;23 we 
assumed a clinically relevant result to be an increase of 
15% in the proportion of patients free from disease pro-
gression or recurrence at 12 months as compared with the 
results of Stupp et al.25 (27%), with a 5% probability of a 
Type I error and a 10% probability of a Type II error.
Thirty-five patients were included in the first part of 
the study. Inclusion criteria were as follows: supratentori-
al, newly diagnosed glioblastoma; gross-total or subtotal 
resection (degree of resection was defined as subtotal if 
residual nodular enhancement was noted on postopera-
tive MRI performed within 48 hours after surgery); age 
range 18–70 years; KPS score of 70 or higher; normal 
liver, kidney, and bone marrow functions; and no con-
comitant infections. Life expectancy had to be longer 
than 3 months. Exclusion criteria were as follows: no his-
tological analysis available; previous biopsy procedure 
performed; multifocal or infratentorial glioblastoma; age 
younger than 18 years and older than 70 years; KPS score 
less than 70; concomitant infections; and altered kidney, 
liver, or bone marrow functions.
Treatment Protocol
The proportion of patients free from recurrence at 12 
months was the primary endpoint of the study. Second-
ary endpoints included toxicity and median survival time. 
After obtaining informed consent, the treatment protocol 
included surgery with carmustine wafer positioning; after 
7–15 days from surgery, chemotherapy was started with 
temozolomide at a dose of 75 mg/m2 daily, for up to 6 
months or until development of toxicity or confirmed dis-
ease progression.
Standard external beam radiation therapy was deliv-
ered in 30 sessions, starting within 30 days from surgery 
for a total dose of 60 Gy. Prophylaxis with trimethoprim 
and sulfamethoxazole was delivered to all patients for the 
duration of the chemotherapy treatment. Patients were 
assessed clinically every month and underwent contrast-
enhanced brain MRI every 2 months.
Disease progression was evaluated according to the 
criteria of McDonald et al.12 In cases of suspected early 
progression (within 3 months from the end of radiation 
therapy), repeat MRI was performed at 45 days to rule 
out pseudoprogression. Complete blood cell count was as-
sessed weekly, liver function every 2 weeks, and lympho-
cyte subsets (CD4 and CD8) and creatinine levels every 3 
weeks. Toxicities were defined according to CTCAE ver-
sion 3.0. In cases of protracted Grade I toxicity, the temo-
zolomide dose was reduced by 25%.
MGMT Promoter Methylation Status
Tumor genomic DNA was extracted by tissue using 
the PureLink Genomic DNA Mini Kit (Invitrogen) accord-
ing to the manufacturer’s instructions for formalin-fixed, 
paraffin-embedded tissue lysate and stored at 4°C. The 
methylation status was assessed by the MethylEasy DNA 
Bisulphite Modification Kit (Diagenode). Briefly, 2.2 µl 
of 3 M NaOH was added to 4 µg DNA in 20 µl solution, 
mixed gently, and incubated for 15 minutes at 37°C. We 
then added 220 µl of modification reagent and overlayed 
the solution with 200 µl of mineral oil. The DNA was than 
incubated at 55°C for 16 hours. Four microliters of the 
converted DNA sample was used in each PCR reaction. 
Methylated-specific PCR was performed using primers 
designed for unmethylated or methylated DNA.26 Two in-
dependent PCR reactions were obtained to confirm results.
Methylated-specific PCR products were analyzed on 
an ABI Prism 3130 (Applied Biosystems). Two microli-
ters of methylated- or unmethylated-specific DNA frag-
ment was added to a mix containing 10 µl of formamide 
and 0.3 µl of Gene Scan-500 LIZ Size Standard Marker 
(Applied Biosystems). Peaks of 81 base pairs (Peak 1) and 
96 base pairs (Peak 2), corresponding to methylated and 
unmethylated DNA, respectively, were detected using 
a separation matrix for the 3130 genetic analyzer (3130 
POP-7, Applied Biosystems). Data were analyzed with 
the Gene Scan program for fragment analysis (ABI Prism 
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3130, Applied Biosystems). The ratio between height 
peaks (Peak 1/Peak 2) provides an estimation of allelic 
ratio. Values greater than or equal to 0.1 indicate MGMT 
promoter methylated status, while lower values indicate 
unmethylated status of the promoter.
Statistical Analysis
The analysis of PFS and median survival was per-
formed using Kaplan-Meier survival curves. Descriptive 
statistics were used for evaluation of toxicities. Level of 
significance was set at p < 0.05.
Results
Clinical Data
Thirty-five patients have been recruited into the study 
to date. The clinical features of these patients are detailed 
in Table 1. Overall, there were 25 males and 10 females, 
with ages ranging from 27 to 70 (median 58). The RPA 
class was IV in 26 cases and III in 9 cases. Median KPS 
score was 80. The median follow-up was 15 months 
(range 8–30 months). One patient was lost to follow-up 
1 month after surgery for withdrawal of consent. Of the 
32 patients with a follow-up longer than or equal to 12 
months (including patients who died within 12 months), 
21 experienced tumor progression, with 50% PFS at 12 
months (Fig. 1). The median time to tumor progression 
in the entire cohort of patients was 12.5 months (Fig. 1).
Overall, 21 patients have shown disease progression, 
and 18 (12 males and 6 females) have died (at 8, 8, 10, 
10, 13, 13, 13, 14, 15, 15, 16, 16, 18, 18, 19, 21, 24, and 
28 months). Sixteen of these 18 patients died due to tu-
mor progression, while 1 male patient died suddenly at 
6 months after tumor progression (necropsy was not per-
formed), and 1 patient died at 13 months after repeat sur-
gery for Legionella pneumonia. Disease progression took 
place in proximity of the original surgery in 19 cases, at 
a distant supratentorial site in 1 case, and in the form of 
diffuse leptomeningeal dissemination in 1 case.
Treatment at progression included repeat surgery and 
second-line chemotherapy in 5 cases, whereas second-
line chemotherapy was delivered in 8 cases (in 2 cases 
with bevacizumab and in 6 with fotemustine). Repeat sur-
gery was performed in 3 patients, who did not continue 
other chemotherapy due to poor clinical conditions. Four 
patients were in poor general condition and were followed 
with supportive therapy only. One patient was treated by 
CyberKnife radiosurgery followed by second-line che-
motherapy with fotemustine.
Median survival was 17.8 months (Fig. 2), and was not 
significantly different if calculated in the patients with fol-
low-up equal to or longer than 12 months (data not shown). 
Significant differences were noted in time to tumor pro-
gression at univariate analysis according to RPA class (p 
= 0.03, log rank test), while no significant differences were 
observed in total versus subtotal resection, KPS score of 70 
versus a higher score, and MGMT promoter methylation 
status (8 methylated vs 22 nonmethylated). At univariate 
analysis, survival time in patients was significantly longer, 
at a statistically borderline level, only in patients with a 
methylated MGMT promoter (p = 0.049), whereas it was 
not influenced by KPS score, RPA class, or CD4+ lympho-
cytopenia development (data not shown).
Toxicity Data
The toxicity profile of the treatment schedule is re-
ported in Table 2. Overall, 7 patients had to prematurely 
stop temozolomide therapy due to toxicity; 1 patient de-
veloped Grade 4 thrombocytopenia during radiotherapy, 
and 1 developed nephrotoxicity (CTCAE Grade 3). Two 
other patients developed CTCAE Grade 4 thrombocyto-
penia after 3 months of therapy, and 1 developed CTCAE 
Grade 4 leukopenia and thrombocytopenia at 2 months 
of therapy. One patient developed Grade 2 liver toxicity, 
with alteration of laboratory tests Grade 4 for bilirubin 
and Grade 3 for alanine aminotransferase and aspartate 
aminotransferase, after 45 days of chemotherapy. Finally, 
1 patient developed Grade 4 thrombocytopenia after 5 
months of chemotherapy.
Overall, 5 patients had to reduce their temozolomide 
dose by 25%, due to liver toxicity in 1 patient, leukope-
nia in 3 patients, and thrombocytopenia in 1 patient. A 
dose reduction by 25% was planned in cases of persistent 
Grade 1 toxicity (for platelets) and Grade 2 toxicity (for 
neutrophils) after obtaining 2 blood samples 1 week apart. 
One female patient developed a late Grade 4 leukopenia 
just after the end of the 6-month temozolomide therapy, 
which promptly receded with growth factor administra-
tion. Three patients did not complete the planned treat-
ment with temozolomide due to early tumor progression.
CD4+ lymphocytopenia occurred in 22 of 34 patients. 
In all cases, this was Grade 3 lymphocytopenia and de-
veloped after at least 2 months of chemotherapy, persist-
ing at follow-up. As noted in Table 2, 3 patients developed 
oral-esophageal candidiasis, which was managed with 
oral antimycotic therapy, and 1 patient developed pneu-
monia that receded with antibiotic therapy. One patient 
developed a dorsolumbar herpes zoster infection after 6 
months of chemotherapy; she was treated with antiviral 
therapy and had moderate residual postherpetic pain. One 
patient developed pneumonia soon after the first fotemus-
tine cycle following repeat surgery. This infection was 
successfully managed with antibiotics but required hospi-
talization. One patient died of Legionella pneumonia af-
ter repeat surgery. One patient was treated empirically for 
suspected brain abscess beginning 10 days after surgery, 
with a delay in radiation therapy and chemotherapy of 14 
days and no subsequent complications.
Deep venous thrombosis (n = 4) and/or pulmonary 
embolism (n = 1) occurred in 4 cases, always during metro-
nomic chemotherapy administration. Other complications 
included multiple vertebral collapses likely due to steroid 
treatment in 1 male patient and development of diabetes in 
5 cases (3 of whom were insulin dependent). Seizures were 
present at diagnosis or occurred during follow-up in 21 of 
33 patients, and were well controlled by medical treatment. 
Only 1 patient developed postoperative intracranial hyper-
tension, which was managed by dexamethasone and man-
nitol infusion. A review of the pattern of toxicities reported 
in other studies combining locoregional carmustine with 
the Stupp protocol is shown in Table 3.
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Discussion
This study shows that a high proportion of patients 
with newly diagnosed glioblastoma were free from dis-
ease recurrence at 12 months. A number of mostly ret-
rospective studies have investigated the tolerability and 
efficacy of the combination of the Stupp protocol with 
carmustine wafers locoregionally. In these studies, toler-
ability data are good and some effectiveness of the treat-
ment appears to be likely.3,12,15,17,18,21
As expected in Phase II studies, the rates of PFS at 
12 months vary significantly among studies due to a num-
ber of factors. Among these factors, differences in patient 
populations are the most relevant, together with the vari-
able type of tumor resection. Overall, the percentage of 
patients free from disease recurrence at 12 months varies 
from 29%10 to 35%11 to 40%.19
The 50% of patients free from disease progression 
at 12 months—in the only prospective study reported so 
far to our knowledge—exceeds the best results obtained 
in retrospective studies by combining carmustine wafers 
and the Stupp protocol, except for the data reported by 
Noël et al.17 These encouraging results were obtained with 
a treatment schedule inducing marked lymphocytopenia; 
of note, Sampson and colleagues22 recently reported that 
such schedules may paradoxically enhance tumor-specif-
ic immune responses in patients with glioblastoma.
Despite this improvement, however, patients continue 
to progress and die of their disease, and median survival 
in recurrent glioblastoma does not exceed 10 months, 
TABLE 1: Clinical features of patients included in the study
Case No. Age (yrs), Sex Tumor Site KPS Score Resection RPA Class
1 64, F rt temporal 70 total IV
2 45, F lt frontal 90 total III
3 55, M lt temporal 70 subtotal IV
4 47, M lt parietal 80 subtotal IV
5 52, F rt temporooccipital 90 total IV
6 40, M rt frontal 90 total III
7 61, F rt temporal 80 total IV
8 61, M rt parietal 70 subtotal IV
9 54, F lt frontoparietal 70 subtotal IV
10 50, M rt frontal 80 total III
11 65, M lt frontal 70 total IV
12 65, F rt frontal 70 total IV
13 68, M rt frontal 80 subtotal IV
14 52, F lt temporal 90 total IV
15 27, M lt frontal 90 total III
16 60, M lt temporal 70 total IV
17 45, M rt frontal 80 total III
18 58, M rt frontal 80 total IV
19 57, M lt frontoparietal 80 total III
20 49, M rt tempoparietal 70 total IV
21 67, M rt tempoparietal 70 subtotal IV
22 63, M lt temporal 80 subtotal III
23 48, F lt parietal 70 subtotal IV
24 67, F rt frontotemporal 90 total III
25 50, M lt frontal 00 total IV
26 63, M rt temporal 00 total III
27 49, M rt frontal 80 total IV
28 58, M rt parietal 90 total IV
29 62, M rt temporal 70 total IV
30 70, M rt temporal 90 total IV
31 57, M lt temporal 90 subtotal IV
32 66, M lt parietal 90 total IV
33 61, M rt frontotemporal 60 total IV
34 70, M lt frontal 70 subtotal IV
35 53, F lt temporal 80 total IV
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even in bevacizumab-treated patients.29 Because the gain 
in survival is more debatable, as compared with the trial 
of Stupp et al., it is extremely important to address tox-
icity issues. From this point of view, the present multi-
modal schedule of treatment did not appear to show a 
meaningfully higher burden of side effects as compared 
with a combination of carmustine wafers with the Stupp 
protocol. Notably, the proportion of patients who had to 
interrupt treatment because of toxicities (7 of 35, 20%) 
was not higher than that reported in the trial of Stupp et 
al.,25 in which 22% of patients could not start the adjuvant 
phase of temozolomide chemotherapy (only 4% for early 
progression). The percentage of patients suffering from 
deep venous thrombosis/pulmonary embolism was also 
similar to that reported in previous works.13
Concerning infections, 1 case of herpes zoster, 2 cas-
es of pneumonia of undetermined origin, and 3 cases of 
nondisseminated candidiasis were detected, and all were 
responsive to standard treatment. One patient died due to 
Legionella pneumonia 1 week after repeat surgery; his 
total lymphocyte count was normal. Protracted prophy-
laxis with trimethoprim and sulfamethoxazole may have 
prevented the occurrence of Pneumocystis infections 
(which did not take place in this cohort), even if we can-
not exclude that it may partly be responsible for the ob-
served cases of liver and kidney toxicities.
Although the relatively low frequency of severe in-
fections in patients displaying marked lymphocytopenia 
may be surprising at first glance, previously reported data 
have demonstrated that in long-term survivors of child-
hood malignancies treated using chemotherapy, profound 
CD4+ reduction was detected in nearly 10%, and that in 
those patients no increase in severe infections took place.2 
In fact, some evidence exists showing that after intensive 
chemotherapy delivered for leukemia, residual T cells 
may show hyperactivity with a broad cytokine release, 
thus partly compensating for the profound numeric loss 
in counteracting possible infections.7 The infections de-
veloping in our patients were not limited solely to those 
patients with CD4+ depletion. We did not observe intra-
cranial infections, except for 1 case of a suspected brain 
abscess that was managed conservatively by antibiotic 
treatment due to empirical evidence.
Diabetes remained a clinical problem in our patients, 
possibly due to a slow tapering of steroid dose after sur-
gery to avoid intracranial hypertension (which actually 
took place in only 1 case). Seizures did not represent a 
clinical problem, with a frequency similar to that report-
ed in the literature and no problems in their management. 
One patient died suddenly, a few weeks after radiological 
evidence of tumor progression, in the context of stable 
neurological conditions; a necropsy was not performed 
and the clinically most likely causes include cardiac dis-
ease with rhythm alteration or pulmonary embolism.
A number of mostly retrospective studies have been 
published on the combination of locoregional carmustine 
and postoperative radiotherapy with concomitant temo-
zolomide followed by adjuvant temozolomide. These data, 
including toxicity analysis, have been recently reported 
in a review6 and are summarized in Table 3. Overall, the 
frequency and severity of side effects are highly variable, 
as expected considering the heterogeneity of the patient 
populations. However, toxicities not related to local com-
plications (such as brain abscess, intracranial hypertension, 
and seizures) do not appear to be substantially increased 
as compared with those encountered in patients included 
in the trial of Stupp et al.,25 while side effects were not de-
scribed in detail in the trial of Westphal et al.30
Although putative additive toxicities may be overes-
timated due to the prospective nature of our study, we ob-
served an increase in non-CNS infections in our patient 
cohort. The lack of statistically significant differences in 
the proportion of progression-free patients and in survival 
time according to age, KPS score, and extent of resection 
is likely due to either selection criteria or to the low num-
ber of patients. Only borderline statistical significance 
was achieved for survival time considering the methyla-
tion status of the MGMT promoter.
In our cohort of patients, the adopted schedule of 
treatment did not appear to modify the pattern of recur-
rence. In fact, recurrence occurred in the great majority 
of cases close to the original tumor site, and only in 2 
cases did it occur at a distance. Thus, metronomic chemo-
therapy with temozolomide, which supposedly may have 
Fig. 1. Graph of the time to tumor progression in the entire cohort 
of patients.
Fig. 2. Graph of survival time in the entire cohort of patients.
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an antiangiogenic effect, did not lead to an increase in 
tumor infiltration or dissemination as compared with the 
general pattern in glioblastoma.5,18 It can be speculated 
that the remarkable efficacy of the schedule in prolong-
ing PFS may be due to an increased inhibiting activity of 
MGMT by daily temozolomide, even if further work is 
needed to verify this hypothesis.
Despite very promising effects on PFS, median sur-
vival time was less significantly improved in our study; 
this is partly in agreement with the recently published 
results of the Radiation Therapy Oncology Group 0525 
trial, which has shown a lack of effect of dose-intensified 
temozolomide on survival time, despite a slight improve-
ment in PFS.9 In this study, the median survival time was 
longer if compared with data from the trial of Stupp et al.25 
This may partly be due to inclusion of selected patients in 
our study (that is, those with total or subtotal resection); if 
we compare our median survival time (17.8 months), with 
the survival time of patients in the Stupp et al. trial (15.8 
months) excluding those undergoing biopsy (126 with par-
tial resection and 113 with total resection), the difference is 
approximately 9 weeks.
It remains to be definitively assessed whether the 
increase in PFS after the first diagnosis and the overall 






Abscess Other Infections DVT/TE
Other 
Toxicities Chemotherapy Stopped
1 no no no yes (progression)
2 no no no
3 yes no no yes (kidney)
4 no no no yes (decrease in platelets)
5 no no dorsolumbar herpes zoster DVT (Day 90)
6 no no no kidney yes (decrease in white  
 blood cells)
7 no no no
8 no no no
9 no yes no yes (decrease in platelets)
10 no no oral candidiasis
11 no no no
12 no no oral candidiasis VTE (Day 60) yes (progression)
13 no no no
14 no no no
15 no no no withdrew consent
16 no no no
17 no no no
18 no no no
19 no no pneumonitis
20 no no no
21 no no no DVT
22 no no no
23 no no oral candidiasis yes (progression)
24 no no no
25 no no no
26 no no no yes (decrease in platelets)
27 no no no
28 no no no
29 no no no yes (liver)
30 no no no DVT
31 no no no yes (decrease in platelets)
32 no no no liver yes (progression)
33 no no legionellosis
34 no no no yes (kidney)
35 no no no yes (decrease in platelets)
* DVT = deep venous thrombosis; TE = thromboembolism; VTE = venous TE.
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TABLE 3: Profile of toxicity in patients with malignant glioma treated using carmustine implants followed by concomitant radiation therapy 
and chemotherapy*





Ryken et al., 2008 prospective Phase II study 2007 21 death for multiorgan failure (4.8%) 5
pulmonary embolism (5%) 4
nausea (5%) 4
liver toxicity (10%) 3
thrombocytopenia (5%) 3
McGirt et al., 2009 retrospective 2004–2006 33 myelosuppression (21%) 
 platelets (15%) 4 (12%)
 neutrophils (6%) 2
seizures (6%) NR
brain edema (3%) NR
DVT (3%) NR
pulmonary embolism (10%) NR
infection (3%) NR
Pan et al., 2008 retrospective 2003–2005 21 cerebritis (10%) 3
steroid psychosis (5%) 3
Menei at al., 2010 retrospective 2005–2006 83 seizure (4.8%) NR
intracranial hypertension (9.6%) 4
cyst of aseptic abscess (2.4%) NR
septic abscess (6%) NR
Noël et al., 2012 retrospective 2007–2008 28 myelosuppression (14%) 3–4
Bock et al., 2010 retrospective 2005–2008 44 seizures (16%) NR
intracranial abscess (5%) NR
brain edema (25%) NR
myelosuppression (7%) 3–4
DVT (9%) NR
1 patient died of pulmonary embolism
La Rocca & Mehdorn, 2009 Phase II study of safety & efficacy 2003–2005 41 sterile brain abscess (1) 1–4
hematological (14%) 1–4
aplastic anemia (2%) NR
pneumonia (4%) 1–4






venous thromboembolism (11%) NR
Salvati et al., 2011 retrospective 2006–2008 32 no Grade 3–4 hematological toxicities
Stupp et al., 2005 randomized Phase III study 2000–2002 284 leukopenia (7%) 3–4
thrombocytopenia (12%) 3–4
Westphal et al., 2003 prospective randomized double blind 1997–1999 120 intracranial hypertension (9.2%) NR
* Data reported as control in patients treated with radiotherapy and temozolomide (Stupp et al.) or with radiotherapy and locoregional carmustine (West-
phal et al.). Abbreviation: NR = not reported.
† According to the CTCAE criteria.
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acceptable toxicity profile will translate into a definite 
increase in median survival time, in the absence of long-
term side effects.16 However, the preliminary data from this 
study are encouraging. For this reason further studies are 
warranted.
Conclusions
Level A evidence, derived from randomized con-
trolled Phase III trials, is present for locoregional chemo-
therapy with carmustine wafers, positioned at surgery and 
followed by radiotherapy, as well as for concomitant ra-
diochemotherapy with temozolomide. However, the com-
bination of carmustine wafers with the Stupp regimen 
has only been investigated in retrospective studies, and it 
is doubtful whether this association leads to an increase 
in survival without relevant side effects. This prospec-
tive study has investigated efficacy (with a primary end 
point of PFS at 12 months), toxicity, and overall survival 
in 35 patients with newly diagnosed glioblastoma treated 
by surgery, carmustine wafers, radiotherapy, and 6-month 
metronomic temozolomide chemotherapy, with monthly 
clinical evaluations and MRI every 2 months.
Among inclusion criteria, a KPS score of 70 or higher 
and an age between 18 and 70 years were requested. Me-
dian time to tumor progression was 12.5 months, and me-
dian survival was 17.8 months after a median follow-up 
of 15 months. Early temozolomide discontinuation took 
place in 7 patients, and there were Grade 3 infections in 
4 patients. One patient died from Legionella pneumonia 
after repeat surgery. The PFS at 12 months in this study 
compares favorably with data present in the literature 
concerning single-treatment modalities, although the re-
sults for survival are less convincing. There is a need for 
prospective comparative trials to define more accurately 
the risk:benefit ratio of these 2 treatment schedules.
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